Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.

Aiwu Ruth He,Thomas Yau,Chiun Hsu,Yoon-Koo Kang,Tae-You Kim,Armando Santoro,Bruno Sangro,Ignacio Melero,Masatoshi Kudo,Ming-Mo Hou,Ana Matilla,Francesco Tovoli,Jennifer J. Knox,Bassel F. El-Rayes,Mirelis Acosta-Rivera,Jaclyn Neely,Yun Shen,Marina Tschaika,Anthony B. El-Khoueiry

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.

2020

Aiwu Ruth He
Thomas Yau
Chiun Hsu
Yoon-Koo Kang
Tae-You Kim
Armando Santoro
Bruno Sangro
Ignacio Melero
Masatoshi Kudo
Ming-Mo Hou
Ana Matilla
Francesco Tovoli
Jennifer J. Knox
Bassel F. El-Rayes
Mirelis Acosta-Rivera
Jaclyn Neely
Yun Shen
Marina Tschaika
Anthony B. El-Khoueiry

512Background: NIVO monotherapy is approved in the United States and other countries for pts with HCC treated with sorafenib (SOR) based on CheckMate 040 (NCT01658878) results, which reported 14% o...

Keywords:

Hepatocellular carcinoma
Combination therapy
Checkmate
Nivolumab
Internal medicine
Medicine
Ipilimumab
Oncology
Pathology
in patient
Sorafenib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations